- Related Products
MedEx answers any queries you might have regarding Xolair-300 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Indications of Xolair.
Treatment of persistent atopic bronchial asthma of moderate and severe course, the symptoms of which are not adequately controlled by the using of glucocorticosteroids, in patients aged 6 years and older. The remedy Xolair should be used in patients with a baseline IgE concentration and body weight corresponding to those listed in the table for the selection of the dosing regimen (see section “Dosage regimen”);
– treatment of chronic idiopathic urticaria, resistant to therapy with histamine H1-receptor blockers, in patients aged 12 years and older.
Contraindications of Xolair.
– hypersensitivity to omalizumab or to another component of the remedy;
– Children under 6 years old in patients with atopic asthma (due to lack of relevant data on efficacy and safety);
– Children under 12 years of age in patients with chronic idiopathic urticaria (due to the lack of relevant data on efficacy and safety).
With caution Xolair.
Caution should be used in patients with impaired liver and / or kidney function, with autoimmune diseases or diseases associated with the accumulation of immune complexes.
When applying the remedy Xolair, as with any other protein-containing remedies, there may be local or systemic allergic reactions, including anaphylactic reactions. Before the introduction of the remedy Xolair, it is necessary to prepare in advance the appropriate resuscitation equipment and medicines needed to stop the hypersensitivity reactions. It is necessary to use the remedy with caution in patients with an increased risk of developing helminth invasions (especially in endemic areas).
The dosage of Xolair 300 mg.
Only for subcutaneous injection! The remedy cannot be administered intravenously or intramuscularly.
The dose of Xolair and the periodicity of administration are determined based on the initial concentration of IgE (IU / ml) measured before the start of treatment, as well as body weight (kg).
Depending on the initial concentration of IgE (IU / ml) and body weight (kg), the recommended dose is 75 to 300 mg once every 2 or 4 weeks (see Tables 3 and 4).
Xolair should not be used in patients with a baseline IgE concentration and body weight that do not match the dosage regimen listed in the table.